Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Rani Therapeutics Holdings, Inc. (RANI : NSDQ)
 
 • Company Description   
Rani Therapeutics Holdings Inc. is a clinical stage biotherapeutics company. It focused on advancing technologies to enable the development of orally administered biologics. Rani Therapeutics Holdings Inc. is based in SAN JOSE, Calif.

Number of Employees: 71

 
 • Price / Volume Information   
Yesterday's Closing Price: $21.76 Daily Weekly Monthly
20 Day Moving Average: 76,485 shares
Shares Outstanding: 49.00 (millions)
Market Capitalization: $1,066.28 (millions)
Beta:
52 Week High: $36.27
52 Week Low: $9.24
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -31.53% -29.39%
12 Week 11.25% 10.14%
Year To Date % %
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2051 RINGWOOD AVENUE
-
SAN JOSE,CA 95131
USA
ph: 408-457-3700
fax: -
ir@ranitherapeutics.com http://www.ranitherapeutics.com
 
 • General Corporate Information   
Officers
Talat Imran - Chief Executive Officer
Mir Imran - Executive Chairman
Svai Sanford - Chief Financial Officer
Dennis Ausiello - Director
Jean-Luc Butel - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 753018100
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/21
Next Expected EPS Date: 02/21/22
Share - Related Items
Shares Outstanding: 49.00
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $1,066.28 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.25 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.84 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 02/21/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 8.10
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -33.33%
Sales Growth
vs. Year Ago Period: 3,168.33%
vs. Previous Quarter: -%
ROE
09/30/21 - -
06/30/21 - -
03/31/21 - -
ROA
09/30/21 - -
06/30/21 - -
03/31/21 - -
Current Ratio
09/30/21 - 25.21
06/30/21 - 7.43
03/31/21 - -
Quick Ratio
09/30/21 - 25.21
06/30/21 - 7.43
03/31/21 - -
Operating Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Net Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Pre-Tax Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Book Value
09/30/21 - 2.69
06/30/21 - -2.58
03/31/21 - -
Inventory Turnover
09/30/21 - -
06/30/21 - -
03/31/21 - -
Debt-to-Equity
09/30/21 - 0.00
06/30/21 - -
03/31/21 - -
Debt-to-Capital
09/30/21 - 0.00
06/30/21 - 0.89
03/31/21 - -
 

Powered by Zacks Investment Research ©